Security key
09075P204
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI)
CUSIP: 09075P204
Q1 2025 13F Holders as of 31 Mar 2025
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 378,983
- Total 13F value
- $769,811
- Share change
- +378,936
- SEC-reported price per share
- $2.03
- Number of holders
- 31
- Value change
- +$769,716
- Number of buys
- 29
- Shares outstanding
- 21,847,524
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2025
Institutions
31
Top holders
10
BTAI full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
BioXcel Therapeutics, Inc. SEC filings
BioXcel Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 09075P204
Recent filing periods:
Ownership snapshot
Top reported holders of BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
ARMISTICE CAPITAL, LLC
Comparable rows
15/15
Latest evidence
31 Mar 2025
13F
13D/G
Lead comparable stake: 5%
13D/G row: ARMISTICE CAPITAL, LLC
Showing 1-6 of 15 holder rows.
Quick read
ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 5%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 5
ARMISTICE CAPITAL, LLC
5%
Oaktree Capital Group Holdings GP...
2.7%
UBS Group AG
4.7%
VANGUARD GROUP INC
4.4%
BlackRock, Inc.
1.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13F
13D/G
Company
|
5%
from 13D/G
|
$1,613,379
4,315,000 shares
|
— | 31 Dec 2024 |
| Oaktree Capital Group Holdings GP, LLC |
13D/G
Oaktree Capital Holdings, LLC
|
2.7%
|
$28,939
170,230 shares
|
-$434,154 | 31 Mar 2025 |
| UBS Group AG |
13F
Company
|
4.7%
|
$477,558
1,276,893 shares
|
— | 31 Dec 2024 |
| VANGUARD GROUP INC |
13F
Company
|
4.4%
|
$444,112
1,187,466 shares
|
— | 31 Dec 2024 |
| BlackRock, Inc. |
13F
Company
|
1.4%
|
$142,309
380,608 shares
|
— | 31 Dec 2024 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
1.2%
|
$116,667
311,965 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
31
Shares
378,983
Rows available
31
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q1 2026 Across Filers
Q1 2026 holders
40
Q1 2025 holders
31
Holder diff
-9
| Investor | Q1 2026 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q1 2026 value | Q1 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend